Perilymphatic application of α-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin

Hearing Research

Volumn 189, Issue 1-2, 2004, Pages 31-40

  Wolters, Francisca L C ^a   Klis, Sjaak F L ^a   Hamers, Frank P T ^a   De Groot, John C M J ^a   Smoorenburg, Guido F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cisplatin; Cochlea; Compound action potential; Deafness; Osmotic pump; Ototoxicity; Protection

Indexed keywords

ALPHA INTERMEDIN; CISPLATIN;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRODE; EVALUATION; FEMALE; GUINEA PIG; HEARING LOSS; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 1342308225     PISSN: 03785955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5955(03)00396-4     Document Type: Article

References (40)

1. Alam S.A., Ikeda K., Oshima T., Suzuki M., Kawase T., Kikuchi T., Takasaka T. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear. Res. 141:2000;28-38.
2. Cardinaal R.M., de Groot J.C.M.J., Huizing E.H., Veldman J.E., Smoorenburg G.F. Dose-dependent effect of 8-day cisplatin administration upon the morphology of the guinea pig cochlea. Hear. Res. 144:2000;135-146.
3. Cardinaal R.M., de Groot J.C.M.J., Huizing E.H., Veldman J.E., Smoorenburg G.F. Cisplatin-induced ototoxicity: Morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs. Hear. Res. 144:2000;147-156.
4. (4-9) analogue, ORG 2766, on cisplatin ototoxicity in albino guinea pigs. Hear. Res. 144:2000;157-167.
5. de Groot J.C.M.J., Veldman J.E., Huizing E.H. An improved fixation method for guinea pig cochlear tissues. Acta Otolaryngol. (Stockh.). 104:1987;234-242.
6. (4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin. Hear. Res. 106:1997;9-19.
7. De Koning P., Brakkee J.H., Gispen W.H. Methods for producing a reproducible crush in the sciatic and tibial nerve of the rat and rapid and precise testing of return of sensory function. Beneficial effects of melanocortins. J. Neurol. Sci. 74:1986;237-246.
8. De Koning P., Neijt J.P., Jennekens F.G., Gispen W.H. Org 2766 protects from cisplatin-induced neurotoxicity in rats. Exp. Neurol. 97:1987;746-750.
9. Ekborn A., Laurell G., Jonhström P., Wallin I., Eksborg S., Ehrsson H. D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics. Hear. Res. 165:2002;53-61.
10. Ekborn A., Laurell G., Ehrsson H., Miller J. Intracochlear administration of thiourea protects against cisplatin-induced outer hair cell loss in the guinea pig. Hear. Res. 181:2003;109-115.
11. Gispen W.H. Therapeutic potential for melanocortins in peripheral nerve disease. Trends Pharmacol. Sci. 11:1990;221-222.
12. Greenwood D.D. A cochlear frequency-position function for several species - 29 years later. J. Acoust. Soc. Am. 87:1990;2592-2605.
13. Hall R.D. Estimation of surviving spiral ganglion cells in the deaf rat using the electrically evoked auditory brainstem response. Hear. Res. 49:1990;155-168.
14. Hamers F.P.T., Pette C., Bravenboer B., Vecht C.J., Neijt J.P., Gispen W.H. Cisplatin-induced neuropathy in mature rats: Effects of the melanocortin-derived peptide ORG 2766. Cancer Chemother. Pharmacol. 32:1993;162-166.
15. (4-9) analog to affect cisplatin ototoxicity: An electrocochleographic study in guinea pigs. Eur. Arch. Otorhinolaryngol. 251:1994;23-29.
16. Hamers F.P.T., Wijbenga J., Wolters F.L.C., Klis S.F.L., Sluyter S., Smoorenburg G.F. Cisplatin ototoxicity involves organ of Corti, Stria Vascularis and Spiral Ganglion: Modulation by alpha-MSH and ORG 2766. Audiol. Neurootol. 8:2003;305-315.
17. Heijmen P.S., Klis S.F.L., de Groot J.C.M.J., Smoorenburg G.F. Cisplatin ototoxicity and the possibly protective effect of α-melanocyte stimulating hormone. Hear. Res. 128:1999;27-39.
18. Hoeve L.J., Mertens zur Borg I.R.A.M., Rodenburg M., Brocaar M.P., Groen B.G.S. Correlations between cis-platinum dosage and toxicity in a guinea pig model. Arch. Otorhinolaryngol. 245:1988;98-102.
19. 4-9 analogue ORG 2766. Brain Res. 662:1994;109-116.
20. Klis S.F.L., O'Leary S.J., Hamers F.P.T., de Groot J.C.M.J., Smoorenburg G.F. Reversible cisplatin ototoxicity in the albino guinea pig. NeuroReport. 11:2000;623-626.
21. Klis S.F.L., O'Leary S.J., Wijbenga J., de Groot J.C.M.J., Hamers F.P.T., Smoorenburg G.F. Partial recovery of cisplatin-induced hearing loss in the albino guinea pig in relation to cisplatin dose. Hear. Res. 164:2002;138-146.
22. Kohn S., Fradis M., Pratt H., Zidan J., Podoshin L., Robinson E., Nir I. Cisplatin ototoxicity in guinea pigs with special reference to toxic effects in the stria vascularis. Laryngoscope. 98:1988;865-871.
23. Kohn S., Fradis M., Podoshin L., Ben-David J., Zidan J., Robinson E. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct. Pathol. 21:1997;289-299.
24. Meech R.P., Campbell K.C.M., Hughes L.P., Rybak L.P. A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hear. Res. 124:1998;44-59.
25. Meyer zum Gottesberge, A.M., 2000. Hormonal regulation of the inner ear. In: Sterkers, O., Ferrary, E., Dauman, R., Sauvage, J.P., Tran Ba Huy, P. (Eds.), Menière's Disease 1999 - Update. Kugler Publications, The Hague, pp. 49-57.
26. Motohashi H., Hozawa K., Oshima T., Takeuchi T., Takasaka T. Dysgenesis of melanocytes and cochlear dysfunction in mutant microphthalmia (mi) mice. Hear. Res. 80:1994;10-20.
27. O'Leary S.J., Klis S.F.L. Recovery of hearing following cisplatin ototoxicity in the guinea pig. Anticancer Res. 22:2002;1525-1528.
28. Prieskorn D.M., Miller J.M. Technical report: chronic and acute intra-cochlear infusion in rodents. Hear. Res. 140:2000;212-215.
29. Roberson D.W., Alosi J.A., Messana E.P., Cotanche D.A. Effect of violation of the labyrinth on the sensory epithelium in the chick cochlea. Hear. Res. 141:2000;155-164.
30. Saito T., Aran J.M. Comparative ototoxicity of cisplatin during acute and chronic treatment. ORL. 56:1994;315-320.
31. Schmiedt R.A., Okamura H.-O., Lang H., Schulte B.A. Ouabain application to the round window of the gerbil cochlea: A model of auditory neuropathy and apoptosis. J. Assoc. Res. Otolaryngol. 3:2002;223-233.
32. Schweitzer V.G. Cisplatin-induced ototoxicity: The effect of pigmentation and inhibitory agents. Laryngoscope. 103:(Suppl. 59):1993;1-52.
33. Smoorenburg G.F., de Groot J.C.M.J., Hamers F.P.T., Klis S.F.L. Protection and spontaneous recovery from cisplatin-induced hearing loss. Ann. N. Y. Acad. Sci. 884:1999;192-210.
34. (4-9) analog on cisplatin ototoxicity in relation to the cisplatin dose: An electrocochleographic study in albino guinea pigs. Hear. Res. 124:1998;108-117.
35. Tange R.A. Differences in the cochlear degeneration pattern in the guinea pig as a result of gentamicin and cis-platinum intoxication. Clin. Otolaryngol. 9:1984;323-327.
36. Tange R.A., Vuzevski V.D. Changes in the stria vascularis of the guinea pig due to cisplatinum. Arch. Otorhinolaryngol. 239:1984;41-47.
37. Ter Laak M.P., Brakkee J.H., Adan R.A.H., Hamers F.P.T., Gispen W.H. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur. J. Pharmacol. 462:2003;179-183.
38. Wolters F.L.C., de Vocht T.F., Klis S.F.L., Hamers F.P.T., Smoorenburg G.F. Co-treatment with Melanotan-II (MT-II), a potent melanocortin, does not protect against cisplatin ototoxicity. Hear. Res. 172:2002;110-117.
39. Wolters F.L.C., Klis S.F.L., Hamers F.P.T., de Groot J.C.M.J., Prieskorn D.M., Miller J.M., Smoorenburg G.F. Systemic co-treatment with α-melanocyte stimulating hormone delays hearing loss caused by local cisplatin administration in guinea pigs. Hear. Res. 179:2003;53-61.
40. Zheng J.L., Gao W.Q. Differential damage to auditory neurons and hair cells by ototoxins and neuroprotection by specific neurotrophins in rat cochlear organotypic cultures. Eur. J. Neurosci. 8:1996;1897-1905.